Adefovir-Induced Hypophosphatemic Osteochondrosis: Clinical Mimicry of Ankylosing Spondylitis

Study Background and Research Question

Adefovir (GS-0393), an acyclic nucleoside phosphonate, is a well-established HBV antiviral agent with a primary mechanism of inhibiting hepatitis B virus (HBV) DNA polymerase via chain termination internal_article. Its use is standard in chronic hepatitis B management, especially in cases resistant to first-line therapies. However, the metabolic and skeletal safety profile of long-term Adefovir therapy remains under-characterized in clinical contexts. The reference study (paper) addresses a pivotal question: Can extended Adefovir exposure induce skeletal pathologies that closely mimic rheumatologic diseases such as ankylosing spondylitis (AS), potentially leading to misdiagnosis and inappropriate management?

Key Innovation from the Reference Study

The central innovation of this case report is the detailed demonstration that Adefovir-induced hypophosphatemic osteochondrosis can present with clinical, biochemical, and imaging features nearly indistinguishable from AS. The study uniquely documents the reversal of both symptoms and radiologic findings upon cessation of Adefovir, providing compelling evidence for causality (paper).

Methods and Experimental Design Insights

This investigation was conducted as a detailed single-patient case analysis. A 35-year-old female with a three-year history of chronic hepatitis B, on daily Adefovir (10 mg), developed progressive low back pain, impaired gait, and lower limb weakness. The diagnostic workup involved:

• Comprehensive clinical examination (positive "4" and pelvic compression tests, muscle strength assessment)
• Laboratory studies: HLA-B27 typing, serum phosphorus, alkaline phosphatase (ALP), C-reactive protein (CRP), calcium, and parathyroid function
• Imaging: Sacroiliac joint MRI and ^99mTc-MDP whole-body bone scintigraphy to evaluate bone metabolism and structural integrity
• Therapeutic challenge: Discontinuation of Adefovir, substitution with entecavir, and adjunctive bone metabolism support (zoledronic acid and alfacalcitol)
• Longitudinal monitoring: Serial biochemical and imaging follow-up over six months

This approach allowed temporal correlation between drug withdrawal and resolution of clinical and biochemical abnormalities, strengthening the inference of drug-induced pathology.

Core Findings and Why They Matter

The patient initially fulfilled several AS classification criteria, including HLA-B27 positivity, high ASDAS score, and characteristic MRI findings (bilateral sacroiliac joint changes, bone marrow edema). However, nonresponse to standard AS therapies (NSAIDs, TNF-α inhibitor) prompted further investigation. Key findings included:

• Severely decreased serum phosphorus (0.29 mmol/L; normal 0.85–1.51 mmol/L) and elevated ALP (440 U/L; normal 35–100 U/L), with otherwise normal inflammatory markers and calcium (paper).
• Bone scintigraphy revealed diffuse metabolic activity, osteoporosis, and multiple small fractures—features atypical for classic AS.
• Following Adefovir discontinuation and metabolic support, the patient’s pain resolved, gait normalized, and both imaging and biochemical markers returned to baseline within six months.

The study elucidates the pathophysiologic mechanism: Adefovir’s renal excretion via OAT1 can induce proximal tubular dysfunction, impairing phosphate reabsorption and leading to hypophosphatemic osteochondrosis (paper). This process can clinically and radiologically mimic spondyloarthropathies, underscoring the importance of considering metabolic etiologies in atypical or refractory rheumatologic presentations.

Comparison with Existing Internal Articles

Internal resources extensively document Adefovir’s utility and mechanistic profile in hepatitis B virus research:

• Adefovir (GS-0393, PMEA): Powering Next-Gen HBV Antiviral Research highlights its robust DNA polymerase inhibition pathway and its value in modeling antiviral drug mechanisms, including in resistant HBV strains. However, it does not address metabolic or skeletal safety concerns.
• Adefovir in Translational HBV Research: Mechanistic Precision and Safety discusses emerging evidence for metabolic safety issues, referencing the need for translational vigilance regarding bone and renal adverse effects, thus aligning with the present case study's findings.
• Adefovir in HBV Research: Pharmacodynamics, Transport, and Risk offers a mechanistic overview of OAT1-mediated renal handling of Adefovir, further substantiating the plausibility of nephrotoxicity and downstream hypophosphatemia.

Collectively, these articles reinforce the need for careful metabolic monitoring in long-term research and clinical protocols involving nucleotide analog antivirals.

Limitations and Transferability

As a single-case report, generalizability is constrained. The lack of a cohort or control group limits the ability to estimate incidence or risk factors. However, the clear temporal association, biologically plausible mechanism, and full reversibility upon drug withdrawal give strong evidence for causality (paper). Transferability is most relevant to clinical and translational researchers using Adefovir in long-term models or patient cohorts, especially those investigating metabolic endpoints or bone health. The findings also emphasize the necessity of integrating biochemical surveillance (serum phosphorus, ALP) in both experimental and clinical settings involving HBV antiviral agents.

Protocol Parameters

• in vitro HBV polymerase inhibition | IC₅₀ = 0.1 µmol/L | suitable for mechanistic and resistance studies | aligns with antiviral potencies required for HBV target engagement | product_spec
• cell-based antiviral assay | 0.2–2.5 µmol/L | standard for in vitro efficacy screening | matches clinically achievable and pharmacodynamically relevant concentrations | product_spec
• renal transporter (OAT1) substrate assays | Kₘ = 170 nmol/L, Vₘₐₓ = 2.40 µmol/h | transporter phenotyping, drug-drug interaction studies | reflects validated probe substrate properties for OAT1 | product_spec
• biochemical monitoring (serum phosphorus, ALP) | workflow_recommendation | applicable to long-term in vivo HBV models | ensures early detection of metabolic side effects | workflow_recommendation

Why this cross-domain matters, maturity, and limitations

The intersection of antiviral pharmacology and musculoskeletal medicine is clinically significant, as adverse metabolic effects from nucleotide analogs can confound rheumatologic diagnoses. The maturity of this cross-domain evidence is currently limited to case-level observations, yet the mechanistic reasoning is supported by both clinical outcomes and transporter-based pharmacology (internal_article). Wider studies are needed to quantify risk and establish universal monitoring protocols.

Research Support Resources

For researchers modeling HBV infection, antiviral drug mechanisms, or renal transporter function, Adefovir (SKU C6629) is available from APExBIO, supplied at high purity and with validated solubility for both cell-based and transporter assays. Its dual role as a selective HBV DNA polymerase inhibitor and a probe substrate for OAT1 makes it suitable for in vitro studies and metabolic safety investigations. Incorporating routine biochemical monitoring (e.g., serum phosphorus, ALP) is recommended in long-term protocols to mitigate risk, as highlighted by the referenced study (paper).